|
|
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 10 µg/dawkę | 10 fiol. (100 dawek) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 30 µg/dawkę | 5 fiol. 30 dawek (6 dawek/fiol.) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 30 µg/dawkę | 15 fiol. (75 dawek) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 30 µg/dawkę | 195 fiol. (975 dawek) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | dyspersja do inf. w amp.-strzyk. | 30 µg/dawkę | 10 amp.-strzyk. 0,418 ml | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 10 fiol. 2,25 ml | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 195 fiol. 2,25 ml | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 10 fiol. 2,25 ml | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 195 fiol. 2,25 ml | 100%X |
|
Rx
|
| COVID-19 vaccine (Ad26.COV2-S [recombinant]) | inj. [zaw.] | | 10 fiol. 2,5 ml (5 dawek) | 100%X |
|
Rx
|
| COVID-19 Vaccine (recombinant, adjuvanted) | inf. [dyspersja] | 5 µg/0,5 ml | 10 fiol. 5 ml | 100%X |
|
Rx
|
| COVID-19 Vaccine (recombinant, adjuvanted) | inf. [dyspersja] | 5 µg/0,5 ml | 2 fiol. 2,5 ml (5 dawek/fiol.) | 100%X |
|
Rx
|
| COVID-19 Vaccine (recombinant, adjuvanted) | inf. [dyspersja] | 5 µg/0,5 ml | 10 fiol. x 2,5 ml (5 dawek/fiol.) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | | 1 fiol. 5 ml (10 dawek) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspresja] | (50/50 µg)/dawkę | 10 fiol. 5 ml (10 dawek) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspresja] | (50/50 µg)/dawkę | 10 fiol. 2,5 ml (5 dawek) | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | dyspersja do inf. | 50 µg | 10 amp.-strzyk. 0,5 ml (1 dawka/amp.-strzyk. | 100%X |
|
Rx
|
| COVID-19 mRNA vaccine (nucleoside-modified) | dyspersja do inf. | 50 µg | 10 fiol. 2,5 ml (5 dawek 0,5 ml lub 10 dawek 0,25 ml/fiol.) | 100%X |
|
Rx
|
| COVID-19 vaccine (ChAdOx1-S [recombinant]) | inj. [zaw.] | | 5 fiol. 5 ml (50 dawek, 10 dawek/fiol.) | 100%X |
|
Rx
|
| COVID-19 vaccine (ChAdOx1-S [recombinant]) | inj. [zaw.] | | 10 fiol. 5 ml | 100%X |
|
|
|
Rx
|
| Dengue tetravalent vaccine (live, attenuated) | inj. [prosz. + rozp. do przyg. roztw.] | | 1 fiol. prosz. + 1 amp.-strzyk. 0,5 ml + 2 igły | 100%X |
|
|
|
Rx
|
| Respiratory syncytial virus vaccines | inj. [prosz. + rozp. do przyg. roztw.] | | 1 fiol. + 1 amp.-strzyk. + adapter + igła | 100%X |
